High-resolution pictures

13 x 15 cm, 300 dpi, 460KB

A. The magnetic nanoparticles are preloaded into the cartridge during its manufacture and automatically disperse into the sample as the cartridge fills with blood. Coated with appropriate ligand molecules, they bind to target protein molecules in the sample.

13 x 15 cm, 300 dpi, 500 KB

B. A small electromagnet situated beneath the cartridge generates a magnetic field that attracts all the magnetic nanoparticles to the biosensor’s active surface, which is coated with ligand molecules that bind to a second binding site on the target protein.

13 x 15 cm, 300 dpi, 490 KB

C. An electromagnet situated above the cartridge generates a magnetic field that pulls unbound magnetic nanoparticles away from the active surface. In this way, a very fast and accurately controlled separation between bound and unbound magnetic nanoparticles is achieved.

13 x 15 cm, 300 dpi, 330 KB

The target protein molecules end up locked in a sandwich between the active surface on one side and attached nanoparticles on the other. The number of attached nanoparticles is measured using an optical technique based on frustrated total internal reflection.

13 x 10 cm, 300 dpi, 500KB

In critical-care settings, such as Emergency Departments within hospitals (step A), there is a persistent clinical need for diagnostic solutions that enable fast and accurate patient triage – for example, diagnosing acute coronary syndromes (i.e. a heart attack). To this end, Philips and bioMérieux will be developing fully automated handheld diagnostic test devices designed for testing at the point-of-care (steps B and C).  They are intended to assist clinicians in time-critical decision-making, for example, to decide whether an obstructed coronary artery needs to be opened in a catheterization laboratory (cathlab, step D).

13 x 10 cm, 300 dpi, 400KB

In critical-care settings, such as Emergency Departments within hospitals (step A), there is a persistent clinical need for diagnostic solutions that enable fast and accurate patient triage – for example, diagnosing acute coronary syndromes (i.e. a heart attack). To this end, Philips and bioMérieux will be developing fully automated handheld diagnostic test devices designed for testing at the point-of-care (steps B and C).  They are intended to assist clinicians in time-critical decision-making, for example, to decide whether an obstructed coronary artery needs to be opened in a catheterization laboratory (cathlab, step D).

13 x 10 cm, 300 dpi, 500 KB

In critical-care settings, such as Emergency Departments within hospitals (step A), there is a persistent clinical need for diagnostic solutions that enable fast and accurate patient triage – for example, diagnosing acute coronary syndromes (i.e. a heart attack). To this end, Philips and bioMérieux will be developing fully automated handheld diagnostic test devices designed for testing at the point-of-care (steps B and C).  They are intended to assist clinicians in time-critical decision-making, for example, to decide whether an obstructed coronary artery needs to be opened in a catheterization laboratory (cathlab, step D).

13 x 10 cm, 300 dpi, 470 KB

In critical-care settings, such as Emergency Departments within hospitals (step A), there is a persistent clinical need for diagnostic solutions that enable fast and accurate patient triage – for example, diagnosing acute coronary syndromes (i.e. a heart attack). To this end, Philips and bioMérieux will be developing fully automated handheld diagnostic test devices designed for testing at the point-of-care (steps B and C).  They are intended to assist clinicians in time-critical decision-making, for example, to decide whether an obstructed coronary artery needs to be opened in a catheterization laboratory (cathlab, step D).